Jeffrey R. Jackson

An immune-active tumor microenvironment favors clinical response to ipilimumab

Rui‐Ru Ji, Scott D. Chasalow, Lisu Wang et al. · Cancer Immunology Immunotherapy · 2011 · 775 citations · Full text

Immune Evasion, Tumor Immunology, Cancer Immunosurveillance +8

The codependence of angiogenesis and chronic inflammation

Jeffrey R. Jackson, Michael Seed, Charles H. Kircher et al. · The FASEB Journal · 1997 · 695 citations

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight, Nicholas D. Adams, Joelle L. Burgess et al. · ACS Medicinal Chemistry Letters · 2010 · 367 citations · Full text

Highly Potent Inhibitor, Tumor Biology, Mammalian Target +16

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

Kenneth W. Wood, Latesh Lad, Lusong Luo et al. · Proceedings of the National Academy of Sciences · 2010 · 252 citations · Full text

Antitumor Activity, Cenp-e Motor Activity, Molecular Biology +18

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

Jeffrey R. Jackson, Aidan G. Gilmartin, Christina S. Imburgia et al. · PubMed · 2000 · 233 citations

Apoptosis, Cell Death, Cell Cycle +18